Examination of the cytokine brain-derived neurotrophic factor after SARS-CoV-2 infection

Klinik für Allgemeine Psychiatrie, Universitätsklinikum Heidelberg0 个研究点目标入组 72 人开始时间: 2022年7月21日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Ability to provide informed consent, age = 18 years, history of SARS-CoV-2 infection.
•Group 1: new or worsened psychiatric symptoms concerning affectivity, energy levels and tiredness, cognition or anxiety and stress related problems that have started after SARS-CoV-2 infection and are persistent on the day of examination, but no shorter than 12 weeks (so called post-covid-syndrom).
•Group 2: no residual symptoms of after SARS-CoV-2 infection.

•1. unable to provide informed consent
•2. acute, severe somatic or psychiatric illnesses, such as:
•psychiatric:
•- acute psychosis
•- acute suicidal ideation
•- acute mania
•- acute intoxication
•- severe anxiety/OCD/depressive symptoms impeding the examination
•-acute neurologic or somatic illnesses that require medical attention such as acute infections, pain or injuries
•-persistent or chronic conditions that may impede the examination (particularly sensory or motor deficits)
•3. Any physical condition or disorder that results in increased risk regarding the exercise test, e.g. angina pectoris, symptomatic arrhythmia, symptomatic valvular aortic stenosis, heart failure, coronary artery disease, severe hypertension (RR > 200/110mmHg), hypertrophic cardiomyopathy, symptomatic congenital or developed cardiac defects, COPD, severe asthma, recently developed acute thoracic pain or dyspnea
•4. General health problems that impede the examination or render it impossible, such as severe allergies, obesity, or orthopedic diseases or disabilities

发起方

Klinik für Allgemeine Psychiatrie, Universitätsklinikum Heidelberg